|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.07.26 - 08:03
|
Corporate News: PUMA SE (EQS)
|
|
|
PUMA Q2 2026 geprägt von Reset-Maßnahmen und schwächerer Nachfrage – starker Freier Cashflow – Ausblick für 2026 bestätigt...
|
|
|
30.07.26 - 11:15
|
Adidas-Aktie: Enttäuschendes Ergebnis reißt Puma mit in den Abgrund (Sharedeals)
|
|
|
Die Adidas-Aktie steht heute unter heftigem Druck. Im vorbörslichen Handel auf Tradegate rutschte der Kurs um 9 Prozent auf 165,90 € ab, und damit so tief wie zuletzt Anfang Juni. Mitgezogen wurde auch der Konkurrent Puma, dessen Papiere auf Tradegate um 2,9 Prozent nachgaben. Umsatz rauf, Gewinn enttäuscht Adidas hat zwar die Umsatzprognose angehoben, doch […]
The post Adidas-Aktie: Enttäuschendes Ergebnis reißt Puma mit in den Abgrund first appeared on sharedeals.de....
|
|
|
|
|
|
|
27.07.26 - 12:54
|
Genesco Announces schuh Leadership Transition (Business Wire)
|
|
|
--Accomplished Footwear Executive Tomas Petersson Appointed President as Colin Temple Retires--
--Petersson Most Recently Served as General Manager Foot Locker EMEA--NASHVILLE, Tenn.--(BUSINESS WIRE)--Genesco (NYSE: GCO) announced today the appointment of Tomas Petersson as president of schuh, the Company's U.K. business selling branded footwear to the youth consumer. Petersson succeeds Colin Temple, who is retiring after a successful 38-year tenure with the business.
A proven consumer brand and omnichannel executive, Petersson brings extensive high-impact global leadership experience across multi-branded footwear retail businesses with a focus on youth culture. Most recently he was Foot Locker's Senior Vice President and General Manager, EMEA, leading the company's largest international business, and previously served as Foot Locker's Global General Manager of atmos, the company's premium sneaker business, among other senior executive roles with Foot Locker, INTERSPORT and PUMA.
Petersson will join ...
|
|
|
|
|
|
|
24.07.26 - 08:36
|
Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu (Cision)
|
|
|
·
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the Paediatric Use Marketing Authorisation (PUMA) application for CT001/KemSu (intranasal sufentanil/ketamine).
·
Proveca intends to request a re-examination of the CHMP opinion in accordance with EMA procedures.
·
Proveca and Cessatech remain committed to working closely with the EMA throughout the re-examination process.
·
CT001/KemSu continues to represent an important potential treatment option for children with moderate to severe acute pain...
|
|
|
|
|
17.07.26 - 11:51
|
PUMA SE Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Puma nach Gesprächen mit Investoren auf "Neutral" mit einem Kursziel von 26 Euro belassen. Nach Ansicht der Anleger bleibe die Stimmung im Sektor verhalten, schrieb Wendy Liu in ......
|
|